Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Buy
62
CPMD Quote, Financials, Valuation and Earnings
Last price:
$0.0100
Seasonality move
:
75.55%
Day range:
$0.0052 - $0.0100
52-week range:
$0.0003 - $0.0090
Dividend yield:
0%
P/E ratio:
11.27x
P/S ratio:
2.51x
P/B ratio:
--
Volume:
598.8K
Avg. volume:
170.8K
1-year change:
-36.59%
Market cap:
$4.3M
Revenue:
$820.1K
EPS (TTM):
-$0.01
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CPMD
CannaPharmaRx, Inc.
|
-- | -- | -- | -- | -- |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$74.7M | $0.22 | 24.77% | 2133.71% | $16.67 |
|
EDSA
Edesa Biotech, Inc.
|
-- | -- | -- | -- | $11.00 |
|
LEXX
Lexaria Bioscience Corp.
|
$100K | -- | -42.53% | -- | $4.50 |
|
ONCY
Oncolytics Biotech, Inc.
|
-- | -$0.05 | -- | -13.85% | $5.55 |
|
XENE
Xenon Pharmaceuticals, Inc.
|
-- | -$1.16 | -- | -43.57% | $55.40 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CPMD
CannaPharmaRx, Inc.
|
$0.0065 | -- | $4.3M | 11.27x | $0.00 | 0% | 2.51x |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$15.82 | $16.67 | $2.1B | 28.19x | $0.00 | 0% | 8.40x |
|
EDSA
Edesa Biotech, Inc.
|
$1.48 | $11.00 | $10.4M | -- | $0.00 | 0% | 31.22x |
|
LEXX
Lexaria Bioscience Corp.
|
$0.56 | $4.50 | $13.9M | -- | $0.00 | 0% | 14.29x |
|
ONCY
Oncolytics Biotech, Inc.
|
$0.91 | $5.55 | $97.4M | -- | $0.00 | 0% | -- |
|
XENE
Xenon Pharmaceuticals, Inc.
|
$44.33 | $55.40 | $3.4B | -- | $0.00 | 0% | 465.87x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CPMD
CannaPharmaRx, Inc.
|
-801.61% | 0.619 | 765% | 0.02x |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
17.62% | -0.123 | 5.37% | 5.02x |
|
EDSA
Edesa Biotech, Inc.
|
-- | -0.273 | -- | 10.60x |
|
LEXX
Lexaria Bioscience Corp.
|
2.06% | -1.067 | 0.6% | 3.11x |
|
ONCY
Oncolytics Biotech, Inc.
|
87.89% | 4.153 | 0.41% | 1.61x |
|
XENE
Xenon Pharmaceuticals, Inc.
|
1.47% | 0.195 | 0.27% | 12.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CPMD
CannaPharmaRx, Inc.
|
-$440K | -$935.6K | -- | -- | -142.49% | -$802.7K |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$65.3M | $30.7M | 17.52% | 21.42% | 41.75% | $44.9M |
|
EDSA
Edesa Biotech, Inc.
|
-$25.9K | -$2.5M | -77.45% | -77.48% | -- | -$1.8M |
|
LEXX
Lexaria Bioscience Corp.
|
$152.6K | -$2.5M | -144.76% | -147.19% | -2155.4% | -$3.6M |
|
ONCY
Oncolytics Biotech, Inc.
|
-$67.5K | -$10M | -540.79% | -635.07% | -- | -$4.9M |
|
XENE
Xenon Pharmaceuticals, Inc.
|
-$641K | -$96.3M | -43.83% | -44.39% | -969.84% | -$72.7M |
CannaPharmaRx, Inc. vs. Competitors
-
Which has Higher Returns CPMD or AUPH?
Aurinia Pharmaceuticals, Inc. has a net margin of -225.07% compared to CannaPharmaRx, Inc.'s net margin of 42.95%. CannaPharmaRx, Inc.'s return on equity of -- beat Aurinia Pharmaceuticals, Inc.'s return on equity of 21.42%.
Company Gross Margin Earnings Per Share Invested Capital CPMDCannaPharmaRx, Inc.-67.01% -$0.00 -$2.5M AUPHAurinia Pharmaceuticals, Inc.88.87% $0.23 $444M -
What do Analysts Say About CPMD or AUPH?
CannaPharmaRx, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Aurinia Pharmaceuticals, Inc. has an analysts' consensus of $16.67 which suggests that it could grow by 5.35%. Given that Aurinia Pharmaceuticals, Inc. has higher upside potential than CannaPharmaRx, Inc., analysts believe Aurinia Pharmaceuticals, Inc. is more attractive than CannaPharmaRx, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CPMDCannaPharmaRx, Inc.0 0 0 AUPHAurinia Pharmaceuticals, Inc.4 3 0 -
Is CPMD or AUPH More Risky?
CannaPharmaRx, Inc. has a beta of -1,775.577, which suggesting that the stock is 177657.686% less volatile than S&P 500. In comparison Aurinia Pharmaceuticals, Inc. has a beta of 1.425, suggesting its more volatile than the S&P 500 by 42.546%.
-
Which is a Better Dividend Stock CPMD or AUPH?
CannaPharmaRx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aurinia Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CannaPharmaRx, Inc. pays -- of its earnings as a dividend. Aurinia Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CPMD or AUPH?
CannaPharmaRx, Inc. quarterly revenues are $656.6K, which are smaller than Aurinia Pharmaceuticals, Inc. quarterly revenues of $73.5M. CannaPharmaRx, Inc.'s net income of -$1.5M is lower than Aurinia Pharmaceuticals, Inc.'s net income of $31.6M. Notably, CannaPharmaRx, Inc.'s price-to-earnings ratio is 11.27x while Aurinia Pharmaceuticals, Inc.'s PE ratio is 28.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CannaPharmaRx, Inc. is 2.51x versus 8.40x for Aurinia Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CPMDCannaPharmaRx, Inc.2.51x 11.27x $656.6K -$1.5M AUPHAurinia Pharmaceuticals, Inc.8.40x 28.19x $73.5M $31.6M
-
Which has Higher Returns CPMD or EDSA?
Edesa Biotech, Inc. has a net margin of -225.07% compared to CannaPharmaRx, Inc.'s net margin of --. CannaPharmaRx, Inc.'s return on equity of -- beat Edesa Biotech, Inc.'s return on equity of -77.48%.
Company Gross Margin Earnings Per Share Invested Capital CPMDCannaPharmaRx, Inc.-67.01% -$0.00 -$2.5M EDSAEdesa Biotech, Inc.-- -$0.32 $12.5M -
What do Analysts Say About CPMD or EDSA?
CannaPharmaRx, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Edesa Biotech, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 643.24%. Given that Edesa Biotech, Inc. has higher upside potential than CannaPharmaRx, Inc., analysts believe Edesa Biotech, Inc. is more attractive than CannaPharmaRx, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CPMDCannaPharmaRx, Inc.0 0 0 EDSAEdesa Biotech, Inc.2 0 0 -
Is CPMD or EDSA More Risky?
CannaPharmaRx, Inc. has a beta of -1,775.577, which suggesting that the stock is 177657.686% less volatile than S&P 500. In comparison Edesa Biotech, Inc. has a beta of 0.078, suggesting its less volatile than the S&P 500 by 92.204%.
-
Which is a Better Dividend Stock CPMD or EDSA?
CannaPharmaRx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edesa Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CannaPharmaRx, Inc. pays -- of its earnings as a dividend. Edesa Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CPMD or EDSA?
CannaPharmaRx, Inc. quarterly revenues are $656.6K, which are larger than Edesa Biotech, Inc. quarterly revenues of --. CannaPharmaRx, Inc.'s net income of -$1.5M is higher than Edesa Biotech, Inc.'s net income of -$2.2M. Notably, CannaPharmaRx, Inc.'s price-to-earnings ratio is 11.27x while Edesa Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CannaPharmaRx, Inc. is 2.51x versus 31.22x for Edesa Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CPMDCannaPharmaRx, Inc.2.51x 11.27x $656.6K -$1.5M EDSAEdesa Biotech, Inc.31.22x -- -- -$2.2M
-
Which has Higher Returns CPMD or LEXX?
Lexaria Bioscience Corp. has a net margin of -225.07% compared to CannaPharmaRx, Inc.'s net margin of -2178.51%. CannaPharmaRx, Inc.'s return on equity of -- beat Lexaria Bioscience Corp.'s return on equity of -147.19%.
Company Gross Margin Earnings Per Share Invested Capital CPMDCannaPharmaRx, Inc.-67.01% -$0.00 -$2.5M LEXXLexaria Bioscience Corp.91.15% -$0.14 $5.3M -
What do Analysts Say About CPMD or LEXX?
CannaPharmaRx, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Lexaria Bioscience Corp. has an analysts' consensus of $4.50 which suggests that it could grow by 703.57%. Given that Lexaria Bioscience Corp. has higher upside potential than CannaPharmaRx, Inc., analysts believe Lexaria Bioscience Corp. is more attractive than CannaPharmaRx, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CPMDCannaPharmaRx, Inc.0 0 0 LEXXLexaria Bioscience Corp.1 0 0 -
Is CPMD or LEXX More Risky?
CannaPharmaRx, Inc. has a beta of -1,775.577, which suggesting that the stock is 177657.686% less volatile than S&P 500. In comparison Lexaria Bioscience Corp. has a beta of 0.628, suggesting its less volatile than the S&P 500 by 37.221%.
-
Which is a Better Dividend Stock CPMD or LEXX?
CannaPharmaRx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexaria Bioscience Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CannaPharmaRx, Inc. pays -- of its earnings as a dividend. Lexaria Bioscience Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CPMD or LEXX?
CannaPharmaRx, Inc. quarterly revenues are $656.6K, which are larger than Lexaria Bioscience Corp. quarterly revenues of $174K. CannaPharmaRx, Inc.'s net income of -$1.5M is higher than Lexaria Bioscience Corp.'s net income of -$2.7M. Notably, CannaPharmaRx, Inc.'s price-to-earnings ratio is 11.27x while Lexaria Bioscience Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CannaPharmaRx, Inc. is 2.51x versus 14.29x for Lexaria Bioscience Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CPMDCannaPharmaRx, Inc.2.51x 11.27x $656.6K -$1.5M LEXXLexaria Bioscience Corp.14.29x -- $174K -$2.7M
-
Which has Higher Returns CPMD or ONCY?
Oncolytics Biotech, Inc. has a net margin of -225.07% compared to CannaPharmaRx, Inc.'s net margin of --. CannaPharmaRx, Inc.'s return on equity of -- beat Oncolytics Biotech, Inc.'s return on equity of -635.07%.
Company Gross Margin Earnings Per Share Invested Capital CPMDCannaPharmaRx, Inc.-67.01% -$0.00 -$2.5M ONCYOncolytics Biotech, Inc.-- -$0.10 $682.8K -
What do Analysts Say About CPMD or ONCY?
CannaPharmaRx, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Oncolytics Biotech, Inc. has an analysts' consensus of $5.55 which suggests that it could grow by 513.1%. Given that Oncolytics Biotech, Inc. has higher upside potential than CannaPharmaRx, Inc., analysts believe Oncolytics Biotech, Inc. is more attractive than CannaPharmaRx, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CPMDCannaPharmaRx, Inc.0 0 0 ONCYOncolytics Biotech, Inc.3 1 0 -
Is CPMD or ONCY More Risky?
CannaPharmaRx, Inc. has a beta of -1,775.577, which suggesting that the stock is 177657.686% less volatile than S&P 500. In comparison Oncolytics Biotech, Inc. has a beta of 0.880, suggesting its less volatile than the S&P 500 by 11.965%.
-
Which is a Better Dividend Stock CPMD or ONCY?
CannaPharmaRx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncolytics Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CannaPharmaRx, Inc. pays -- of its earnings as a dividend. Oncolytics Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CPMD or ONCY?
CannaPharmaRx, Inc. quarterly revenues are $656.6K, which are larger than Oncolytics Biotech, Inc. quarterly revenues of --. CannaPharmaRx, Inc.'s net income of -$1.5M is higher than Oncolytics Biotech, Inc.'s net income of -$10.5M. Notably, CannaPharmaRx, Inc.'s price-to-earnings ratio is 11.27x while Oncolytics Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CannaPharmaRx, Inc. is 2.51x versus -- for Oncolytics Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CPMDCannaPharmaRx, Inc.2.51x 11.27x $656.6K -$1.5M ONCYOncolytics Biotech, Inc.-- -- -- -$10.5M
-
Which has Higher Returns CPMD or XENE?
Xenon Pharmaceuticals, Inc. has a net margin of -225.07% compared to CannaPharmaRx, Inc.'s net margin of -867.29%. CannaPharmaRx, Inc.'s return on equity of -- beat Xenon Pharmaceuticals, Inc.'s return on equity of -44.39%.
Company Gross Margin Earnings Per Share Invested Capital CPMDCannaPharmaRx, Inc.-67.01% -$0.00 -$2.5M XENEXenon Pharmaceuticals, Inc.-- -$1.15 $567.8M -
What do Analysts Say About CPMD or XENE?
CannaPharmaRx, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Xenon Pharmaceuticals, Inc. has an analysts' consensus of $55.40 which suggests that it could grow by 24.98%. Given that Xenon Pharmaceuticals, Inc. has higher upside potential than CannaPharmaRx, Inc., analysts believe Xenon Pharmaceuticals, Inc. is more attractive than CannaPharmaRx, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CPMDCannaPharmaRx, Inc.0 0 0 XENEXenon Pharmaceuticals, Inc.17 0 0 -
Is CPMD or XENE More Risky?
CannaPharmaRx, Inc. has a beta of -1,775.577, which suggesting that the stock is 177657.686% less volatile than S&P 500. In comparison Xenon Pharmaceuticals, Inc. has a beta of 1.027, suggesting its more volatile than the S&P 500 by 2.689%.
-
Which is a Better Dividend Stock CPMD or XENE?
CannaPharmaRx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenon Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CannaPharmaRx, Inc. pays -- of its earnings as a dividend. Xenon Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CPMD or XENE?
CannaPharmaRx, Inc. quarterly revenues are $656.6K, which are larger than Xenon Pharmaceuticals, Inc. quarterly revenues of --. CannaPharmaRx, Inc.'s net income of -$1.5M is higher than Xenon Pharmaceuticals, Inc.'s net income of -$90.9M. Notably, CannaPharmaRx, Inc.'s price-to-earnings ratio is 11.27x while Xenon Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CannaPharmaRx, Inc. is 2.51x versus 465.87x for Xenon Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CPMDCannaPharmaRx, Inc.2.51x 11.27x $656.6K -$1.5M XENEXenon Pharmaceuticals, Inc.465.87x -- -- -$90.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
14
SMX alert for Dec 30
SMX (Security Matters) Plc [SMX] is down 40.26% over the past day.
Buy
71
ZCSH alert for Dec 30
Grayscale Zcash Trust (ZEC) [ZCSH] is down 4.56% over the past day.
Buy
69
GDXU alert for Dec 30
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 3.19% over the past day.
